We are live on ! Find out more
RhumbLine Advisers

RhumbLine Advisers Portfolio holdings

AUM $117B
1-Year Est. Return 29.66%
This Fund
S&P 500
This Quarter Est. Return
+4.83%
1 Year Est. Return
+29.66%
3 Year Est. Return
+101.47%
5 Year Est. Return
+137.35%
10 Year Est. Return
+530.91%
AUM
$46B
AUM Growth
+$2.18B
Cap. Flow
+$425M
Cap. Flow %
0.92%
Top 10 Hldgs %
15.17%
Holding
2,954
New
28
Increased
2,252
Reduced
604
Closed
50

Top Buys

Rank Stock Value
1
DD icon
DuPont de Nemours
DD
+$128M
2
BKR icon
Baker Hughes
BKR
+$26.7M
3
IQV icon
IQVIA
IQV
+$14.5M
4
OKE icon
Oneok
OKE
+$14.3M
5
BRK.B icon
Berkshire Hathaway Class B
BRK.B
+$11.2M

Sector Composition

Rank Sector Weight
1 Financials 16.64%
2 Technology 15.8%
3 Healthcare 13.57%
4 Industrials 10.87%
5 Consumer Discretionary 9.22%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
UBFO
2801
DELISTED
United Security Bancshares
UBFO
$164K ﹤0.01%
17,249
+100
+0.6% +$937
WAAS
2802
DELISTED
AquaVenture Holdings Limited
WAAS
$163K ﹤0.01%
12,102
+140
+1% +$2.13K
AMBR
2803
DELISTED
Amber Road Inc
AMBR
$163K ﹤0.01%
21,230
+555
+3% +$4.56K
SLP icon
2804
Simulations Plus
SLP
$369M
$161K ﹤0.01%
10,409
+180
+2% +$2.61K
TIPT icon
2805
Tiptree Inc
TIPT
$662M
$160K ﹤0.01%
25,676
-540
-2% -$3.53K
WG
2806
DELISTED
Willbros Group
WG
$160K ﹤0.01%
49,680
+120
+0.2% +$288
CASC
2807
DELISTED
Cascadian Therapeutics, Inc.
CASC
$160K ﹤0.01%
39,144
+750
+2% +$2.87K
PHIIK
2808
DELISTED
PHI, Inc. Non-Voting Common Stock
PHIIK
$160K ﹤0.01%
13,605
+270
+2% +$2.94K
CFMS
2809
DELISTED
Conformis, Inc. Common Stock
CFMS
$159K ﹤0.01%
1,805
+14
+0.8% +$1.39K
LAB icon
2810
Standard BioTools
LAB
$340M
$157K ﹤0.01%
31,189
+720
+2% +$3.03K
TRAK icon
2811
ReposiTrak
TRAK
$153M
$157K ﹤0.01%
12,915
+360
+3% +$4.51K
GST
2812
DELISTED
Gastar Exploration Inc.
GST
$156K ﹤0.01%
177,367
+1,770
+1% +$1.32K
NM
2813
DELISTED
Navios Maritime Holdings Inc.
NM
$155K ﹤0.01%
9,308
+1,494
+19% +$21.1K
IMH
2814
DELISTED
Impac Mortgage Holdings Inc.
IMH
$155K ﹤0.01%
11,848
-70
-0.6% -$974
HSTO
2815
DELISTED
Histogen Inc. Common Stock
HSTO
$153K ﹤0.01%
139
+3
+2% +$3.41K
SND icon
2816
Smart Sand
SND
$185M
$151K ﹤0.01%
22,219
+240
+1% +$1.54K
ITI
2817
DELISTED
Iteris, Inc.
ITI
$151K ﹤0.01%
22,742
+820
+4% +$5.14K
SBBP
2818
DELISTED
Strongbridge Biopharma plc.
SBBP
$151K ﹤0.01%
21,856
+330
+2% +$2.28K
RNWK
2819
DELISTED
RealNetworks Inc
RNWK
$150K ﹤0.01%
31,320
-354
-1% -$1.53K
BBW icon
2820
Build-A-Bear
BBW
$425M
$149K ﹤0.01%
16,259
LPG icon
2821
Dorian LPG
LPG
$2.03B
$147K ﹤0.01%
21,606
-2,755
-11% -$20.3K
ZYNE
2822
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$147K ﹤0.01%
17,589
+3,906
+29% +$41.3K
PMBC
2823
DELISTED
Pacific Mercantile Bancorp
PMBC
$145K ﹤0.01%
15,858
-180
-1% -$1.51K
SQBG
2824
DELISTED
Sequential Brands Group, Inc.
SQBG
$145K ﹤0.01%
1,213
+19
+2% +$2.28K
RLH
2825
DELISTED
Red Lions Hotel Corporation
RLH
$145K ﹤0.01%
16,816
+10
+0.1% +$73

Similar funds

RhumbLine Advisers's Q3 2017 Portfolio in Review

As of Q3 2017, RhumbLine Advisers held 2,954 positions worth $46B, up 5% from $43.8B the previous quarter. Its ten largest holdings account for 15% of the portfolio.

Trading was light in Q3 2017: portfolio turnover was 2.6%. RhumbLine Advisers opened 28 new positions and exited 50, leaving the 2,954-position portfolio largely intact.

By sector, the portfolio is most concentrated in Financials at 17% of assets, up from 16% a quarter earlier, followed by Technology and Healthcare.

  • RhumbLine Advisers's largest Q3 2017 buy was Baker Hughes: 750,985 shares worth $27.5M.
  • RhumbLine Advisers added most to DuPont de Nemours in Q3 2017, an estimated $128M increase.
  • RhumbLine Advisers's biggest Q3 2017 reduction was UnitedHealth, cutting an estimated $22.8M.
  • RhumbLine Advisers fully exited Du Pont De Nemours E I in Q3 2017, selling an estimated $114M.
  • RhumbLine Advisers's ten largest holdings make up 15% of its $46B portfolio in Q3 2017.
  • RhumbLine Advisers opened 28 new positions and closed 50 in Q3 2017.
  • RhumbLine Advisers's portfolio value rose 5% quarter-over-quarter to $46B.

Based on RhumbLine Advisers's 13F filing for Q3 2017, filed 6 Nov 2017.